Dishman Carbogen Amcis Limited has informed the Exchange regarding Outcome of Board Meeting held on May 19, 2026.
DCAL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 12.4 pts more than Nifty Microcap 250 and 12.7 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The Board approved FY2026 audited results showing consolidated net profit of Rs.97.45 Crores (vs Rs.3.24 Crores), driven by strong CDMO business performance with total income of Rs.2,987.84 Crores. However, standalone operations reported a loss of Rs.38.40 Crores on revenue decline to Rs.316 Crores, raising concerns about entity-level performance. The company plans to raise ECB of up to CHF 200 million (approx Rs.2,452 Crores) from promoter entity Aamanya AG to refinance existing debt at better interest rates. Auditors issued unmodified opinion but drew emphasis on goodwill accounting treatment and standalone financial covenant non-compliance for debentures worth Rs.84.44 Crores.
Mixed signals for investors: Strong consolidated profitability is positive, but standalone losses and covenant non-compliance at entity level raise concerns. The large ECB from promoter group increases related party exposure and borrowing costs will impact future interest expenses.